S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
Introducing MarketBeat All Access (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
66,000% upside on tiny biotech? (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
Introducing MarketBeat All Access (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
66,000% upside on tiny biotech? (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
Introducing MarketBeat All Access (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
66,000% upside on tiny biotech? (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
Introducing MarketBeat All Access (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
66,000% upside on tiny biotech? (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right

Vigil Neuroscience (VIGL) Stock Forecast, Price & News

$9.36
+0.12 (+1.30%)
(As of 05/26/2023 08:48 PM ET)
Compare
Today's Range
$8.71
$9.37
50-Day Range
$8.11
$12.20
52-Week Range
$2.25
$16.77
Volume
23,700 shs
Average Volume
22,552 shs
Market Capitalization
$334.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.80

Vigil Neuroscience MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
100.9% Upside
$18.80 Price Target
Short Interest
Bearish
3.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.22) to ($2.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

721st out of 1,012 stocks

Biological Products, Except Diagnostic Industry

113th out of 169 stocks


VIGL stock logo

About Vigil Neuroscience (NASDAQ:VIGL) Stock

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.

Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

VIGL Stock News Headlines

3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
See More Headlines
Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

VIGL Company Calendar

Last Earnings
3/21/2023
Today
5/29/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIGL
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.80
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+100.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-68,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.80 per share

Miscellaneous

Free Float
19,045,000
Market Cap
$334.06 million
Optionable
Not Optionable
Beta
3.33

Key Executives

  • Dr. Ivana Magovcevic-Liebisch J.D. (Age 56)
    Ph.D., Pres, CEO & Director
    Comp: $713.25k
  • Ms. Jennifer Ziolkowski CPA (Age 49)
    CPA, Chief Financial Officer
    Comp: $518.04k
  • Dr. Spyridon Papapetropoulos M.D. (Age 50)
    Ph.D., Chief Medical Officer
    Comp: $601.74k
  • Park Guo CPA
    Accounting Mang.
  • Kelly Neelon Ph.D.
    VP of CMC & Technical Operations
  • Ms. Sarah Carmody
    VP of Investor Relations & Corp. Communications
  • Mr. Christopher Verni J.D. (Age 48)
    Gen. Counsel
  • April Effort M.B.A.
    M.S., Head of Corp. Devel.
  • Mr. Evan A. Thackaberry DABT (Age 50)
    Ph.D., Sr. VP & Head of Early Devel.
  • Mr. Charles Maggs
    Head of FP&A













VIGL Stock - Frequently Asked Questions

Should I buy or sell Vigil Neuroscience stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VIGL shares.
View VIGL analyst ratings
or view top-rated stocks.

What is Vigil Neuroscience's stock price forecast for 2023?

5 equities research analysts have issued 1-year target prices for Vigil Neuroscience's shares. Their VIGL share price forecasts range from $13.00 to $24.00. On average, they expect the company's share price to reach $18.80 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for VIGL
or view top-rated stocks among Wall Street analysts.

How have VIGL shares performed in 2023?

Vigil Neuroscience's stock was trading at $12.50 at the start of the year. Since then, VIGL stock has decreased by 25.1% and is now trading at $9.36.
View the best growth stocks for 2023 here
.

When is Vigil Neuroscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our VIGL earnings forecast
.

How were Vigil Neuroscience's earnings last quarter?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) posted its earnings results on Tuesday, March, 21st. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.14.

When did Vigil Neuroscience IPO?

(VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share.

What is Vigil Neuroscience's stock symbol?

Vigil Neuroscience trades on the NASDAQ under the ticker symbol "VIGL."

Who are Vigil Neuroscience's major shareholders?

Vigil Neuroscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.32%), Barclays PLC (0.29%), Citigroup Inc. (0.26%), Susquehanna International Group LLP (0.16%), Jane Street Group LLC (0.08%) and Bank of America Corp DE (0.05%). Insiders that own company stock include Christopher Verni, Clay Thorp, Evan Thackaberry, Ivana Magovcevic-Liebisch and Spyros Papapetropoulos.
View institutional ownership trends
.

How do I buy shares of Vigil Neuroscience?

Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vigil Neuroscience's stock price today?

One share of VIGL stock can currently be purchased for approximately $9.36.

How much money does Vigil Neuroscience make?

Vigil Neuroscience (NASDAQ:VIGL) has a market capitalization of $334.06 million. The company earns $-68,310,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis.

How many employees does Vigil Neuroscience have?

The company employs 2,021 workers across the globe.

How can I contact Vigil Neuroscience?

The official website for the company is vigilneuro.com. The company can be reached via phone at 857-254-4445 or via email at scarmody@vigilneuro.com.

This page (NASDAQ:VIGL) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -